8-K: Pacira BioSciences Announces Q1 2024 Results and $150 Million Share Repurchase Program

Pacira BioSciences reported a solid start to 2024 with increased revenue and a new $150 million share repurchase program.

Summary

• Pacira BioSciences reported first quarter 2024 total revenues of $167.1 million, up from $160.3 million in the same period last year.
• Net product sales were $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera.
• The company achieved a GAAP net income of $9.0 million, or $0.19 per share, compared to a net loss of $19.5 million in the first quarter of 2023.
• Adjusted EBITDA for the quarter was $44.6 million, an increase from $41.9 million in the prior year.
• Pacira's Board of Directors approved a new share repurchase program authorizing up to $150 million of the company's common stock to be bought back.
• The company is reiterating its full-year 2024 financial guidance, including total revenue between $680 million and $705 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong financial results, a new share repurchase program, and advancements in product development. The company is showing growth and confidence in its future.

Positives

• Pacira saw increased sales across all three of its main products: EXPAREL, ZILRETTA, and iovera.
• The company moved from a net loss to a net income of $9.0 million in the first quarter of 2024.
• The new share repurchase program signals management's confidence in the company's future.
• The RMAT designation for PCRX-201 could accelerate its development and approval.
• The new EXPAREL patents provide long-term protection for the product.
• Cash provided by operations was $49.1 million in the first quarter of 2024, compared to $19.1 million in the first quarter of 2023.

Negatives

• EXPAREL volume growth was 3 percent, but this was offset by contracted discounts and vial mix.
• The company incurred $7.4 million in product development and manufacturing capacity expansion costs in Q1 2024.
• Total operating expenses were $153.9 million in the first quarter of 2024, compared to $163.4 million in the first quarter of 2023.

Risks

• The company's success depends on the market acceptance of EXPAREL, ZILRETTA, and iovera.
• The company faces risks related to manufacturing, supply chain, and economic conditions.
• There are risks associated with integrating acquired businesses.
• The company's future performance is subject to the outcome of any litigation.
• The company's ability to successfully complete capital projects is a risk.

Future Outlook

Pacira is focused on driving accelerated growth in 2025 and beyond, with the implementation of separate Medicare reimbursement for EXPAREL expected to be a significant growth catalyst. The company is also advancing the launch of EXPAREL in new lower extremity nerve block indications and expects to present updated data on PCRX-201 in the Fall.

Management Comments

• Frank D. Lee, chief executive officer of Pacira BioSciences, stated that sales are off to a solid start for all three of their opioid-sparing products.
• Mr. Lee also mentioned that they are pleased with the progress they are making advancing the launch of EXPAREL in two new lower extremity nerve block indications.
• Mr. Lee added that the $150 million stock buyback underscores their belief in their team, products, and growth outlook.

Industry Context

Pacira's focus on non-opioid pain management aligns with a broader industry trend towards reducing opioid use. The company's products, such as EXPAREL, ZILRETTA, and iovera, are positioned to benefit from this trend. The development of PCRX-201 also places Pacira in the growing field of regenerative medicine.

Comparison to Industry Standards

• Pacira's Q1 2024 revenue growth of approximately 4% year-over-year is a solid performance in the pharmaceutical sector, but it is important to compare this to peers such as Heron Therapeutics (HRTX) and Flexion Therapeutics (acquired by Pacira), which also focus on pain management.
• Heron Therapeutics reported Q1 2024 revenue of $38.9 million, which is significantly lower than Pacira's $167.1 million, indicating Pacira's stronger market position.
• While direct comparisons are difficult due to different product portfolios and market strategies, Pacira's adjusted EBITDA of $44.6 million suggests a healthy profitability compared to some of its smaller competitors.
• The share repurchase program is a common practice among mature biotech companies with strong cash flow, similar to what companies like Amgen (AMGN) and Gilead Sciences (GILD) have done in the past.
• The RMAT designation for PCRX-201 is a positive development, putting Pacira in a similar position to companies like Vertex Pharmaceuticals (VRTX) that have received similar designations for their innovative therapies.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and the company's improved financial performance.
• Patients will have increased access to non-opioid pain management options.
• Employees may benefit from the company's growth and success.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company will continue to execute its share repurchase program.
• Pacira will focus on the launch of EXPAREL in new lower extremity nerve block indications.
• The company will prepare for the implementation of separate Medicare reimbursement for EXPAREL in outpatient settings in January 2025.
• Pacira will present updated data on PCRX-201 at a medical meeting in the Fall.

Key Dates

Keywords

Pacira BioSciences, EXPAREL, ZILRETTA, iovera, Share Repurchase, Non-opioid pain management, Regenerative medicine, RMAT designation, Financial results, EBITDA